Technology advancements, broad-based commercialization of wearables and sensors, and the impact of a global pandemic are proving to be pivotal in the shift towards decentralized clinical trials. The ability for remote, unobtrusive and real-time capture of patient data coupled with the need to reduce in-person contact is accelerating the life sciences industry’s interest in new approaches to clinical trials. This use of sensors and real-time data capture vastly improves the quality of clinical data with the potential to reduce site queries and monitoring visits. There is also unprecedented accessibility to vast volumes of patient data – and the ability to apply artificial intelligence and machine learning in the analysis of that data – all powering new safety and clinical insights. In this session, Cognizant will explore current state of technology, the impact of regulatory oversight, and readiness of the industry to drive necessary changes.